Analysts expect Bausch Health Companies Inc. (NYSE:BHC) to announce earnings of $1.09 per share for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Bausch Health Companies’ earnings. The lowest EPS estimate is $0.98 and the highest is $1.19. Bausch Health Companies posted earnings of $1.33 per share in the same quarter last year, which would suggest a negative year over year growth rate of 18%. The firm is expected to report its next earnings report on Wednesday, February 23rd.
On average, analysts expect that Bausch Health Companies will report full-year earnings of $4.23 per share for the current financial year, with EPS estimates ranging from $4.11 to $4.32. For the next financial year, analysts expect that the firm will post earnings of $4.73 per share, with EPS estimates ranging from $4.11 to $5.05. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Bausch Health Companies.
Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Tuesday, November 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.07. The business had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $2.15 billion. Bausch Health Companies had a negative net margin of 13.85% and a negative return on equity of 2,440.75%.
Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Bausch Health Companies by 1.1% in the 2nd quarter. Vanguard Group Inc. now owns 9,307,234 shares of the company’s stock valued at $272,887,000 after acquiring an additional 96,748 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Bausch Health Companies by 48.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 7,850,573 shares of the company’s stock worth $230,179,000 after buying an additional 2,553,297 shares in the last quarter. Laurion Capital Management LP lifted its position in Bausch Health Companies by 10.9% in the 3rd quarter. Laurion Capital Management LP now owns 7,536,780 shares of the company’s stock worth $209,899,000 after buying an additional 741,378 shares in the last quarter. Guardian Capital LP lifted its position in Bausch Health Companies by 13.7% in the 2nd quarter. Guardian Capital LP now owns 4,907,407 shares of the company’s stock worth $144,175,000 after buying an additional 591,054 shares in the last quarter. Finally, Miller Value Partners LLC lifted its position in Bausch Health Companies by 2.5% in the 2nd quarter. Miller Value Partners LLC now owns 3,330,390 shares of the company’s stock worth $97,647,000 after buying an additional 79,969 shares in the last quarter. Institutional investors and hedge funds own 75.43% of the company’s stock.
BHC stock traded up $0.08 on Thursday, hitting $26.11. 1,280,183 shares of the company’s stock traded hands, compared to its average volume of 3,088,960. Bausch Health Companies has a 1-year low of $18.49 and a 1-year high of $34.80. The stock has a market cap of $9.37 billion, a price-to-earnings ratio of -7.96, a P/E/G ratio of 1.45 and a beta of 1.56. The stock has a fifty day moving average of $27.66 and a 200-day moving average of $28.69.
About Bausch Health Companies
Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.